bioAffinity Technologies Files 8-K with Material Agreement
Ticker: BIAFW · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1712762
Sentiment: neutral
Topics: material-agreement, 8-k
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on Oct 8, 2025, reporting a material definitive agreement. Details to follow.
AI Summary
On October 8, 2025, bioAffinity Technologies, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in San Antonio, Texas.
Why It Matters
This 8-K filing signals a significant development for bioAffinity Technologies, Inc., potentially impacting its business operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's future performance.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Antonio, Texas (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement filed by bioAffinity Technologies, Inc.?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 8, 2025.
Where are bioAffinity Technologies, Inc.'s principal executive offices located?
bioAffinity Technologies, Inc.'s principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the Standard Industrial Classification (SIC) code for bioAffinity Technologies, Inc.?
The SIC code for bioAffinity Technologies, Inc. is 8731, which falls under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
What other items are included in this 8-K filing besides the material definitive agreement?
In addition to the material definitive agreement, the filing also includes 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 1,314 words · 5 min read · ~4 pages · Grade level 12.4 · Accepted 2025-10-09 17:04:00
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
- $1.8 million — gregate gross proceeds of approximately $1.8 million before deducting placement agent fees a
- $75,000 — t-of-pocket expenses up to a maximum of $75,000. The foregoing summaries of the Offer
Filing Documents
- form8-k.htm (8-K) — 57KB
- ex1-1.htm (EX-1.1) — 139KB
- ex5-1.htm (EX-5.1) — 19KB
- ex10-1.htm (EX-10.1) — 232KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-2.htm (EX-99.2) — 13KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- ex99-2_001.jpg (GRAPHIC) — 20KB
- 0001493152-25-017627.txt ( ) — 842KB
- biaf-20251008.xsd (EX-101.SCH) — 4KB
- biaf-20251008_def.xml (EX-101.DEF) — 26KB
- biaf-20251008_lab.xml (EX-101.LAB) — 36KB
- biaf-20251008_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 9, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-